Incyte Corporation (INCY) fair value analysis
S&P 500 & Nasdaq · Updated 2026-10-19
INCY price how computed
Forward Fair Value verdict
UndervaluedINCY is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $112.79
- Sector
- Healthcare
- 12-month range
- $90.18–$129.93
- Market cap
- $22.9B
- From 52-week high
- -13.2%
- Shares outstanding
- 203M
- Rank in Healthcare by discount to fair value
- #23 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes medicines focused on oncology, inflammation, and other therapeutic areas. The company operates globally with a presence across multiple regions including North America, Europe, and other international markets.
INCY currently ranks #23 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $22.9B
- P/E (trailing)
- 13x
- Revenue (TTM)
- $5.82B
- Net margin
- 27.7%
- EPS (TTM)
- $8.67
- Gross margin
- 93.7%
- Debt / equity
- 0.01
- Revenue growth (3-yr avg)
- 27.4%
- Shares outstanding
- 203M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 31 · neutral
- 50-day average
- $121.83
- 200-day average
- $107.50
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+59.1%)
2026-03 ▲ beat (+35.1%)
2025-12 ▼ miss (-6.2%)
2025-09 ▲ beat (+37.8%)
2025-06 ▲ beat (+6.8%)
2025-03 ▲ beat (+12.6%)
2024-12 ▼ miss (-7.7%)
2024-09 ▼ miss (-1.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 12 buy · 15 hold · 1 sell (28 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $130
- Target vs last price
- +15.3%
What our data shows for INCY
- Our model validated 17 trailing price-to-earnings windows for INCY, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $90.18–$129.93.
- The 14-day relative strength index sits at a neutral 31.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for INCY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent INCY news
TickrTrends' derived news-sentiment signal for INCY is currently mixed, computed from recent coverage.
- Incyte: Digesting The ESMO Updates In Pancreatic, Colorectal, And Ovarian Cancer (INCY) (seekingalpha.com, 2026-10-20)
TickrTrends take: Incyte presented updates on its pipeline across multiple cancer indications at ESMO, including developments in pancreatic, colorectal, and ovarian cancer that could influence future revenue potential. Given TickrTrends' current undervalued assessment, investors focused on valuation should monitor whether these clinical updates translate into meaningful market opportunities that justify current pricing. The breadth of the company's oncology efforts across different cancer types suggests multiple paths for growth, which could become material to reassessing the stock's fair value relative to its current market position. - Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Trial Miss in IPF (gurufocus.com, 2026-10-12)
TickrTrends take: Incyte Corporation operates in the Healthcare sector where clinical trial outcomes significantly influence investor sentiment and valuation multiples. While this headline concerns a competitor in the respiratory/IPF space, setbacks in phase trials across the healthcare industry can create broader pressure on valuations and investor confidence in similar therapeutic areas. Given TickrTrends' current assessment of INCY as undervalued, observers should monitor whether INCY's pipeline programs face similar clinical headwinds or whether market weakness in healthcare provides a valuation opportunity. - Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis (manilatimes.net, 2026-10-12)
TickrTrends take: Syndax's positive topline results from the MAXPIRe Phase 2 trial of axatilimab represent a potential pipeline advancement for INCY, which acquired Syndax in 2021, and could support revenue diversification in its immunology portfolio. Given TickrTrends' undervalued assessment of INCY, investors focused on valuation may want to monitor whether this clinical progress translates into updated guidance or analyst estimates that could close any valuation gap. The idiopathic pulmonary fibrosis market represents a substantial opportunity, so successful phase progression could have meaningful implications for INCY's long-term commercial prospects and near-term market sentiment.
More INCY news
- Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S. (thehindu.com, 2026-10-07)
What people are saying
Follow the INCY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — INCY's indicator trends this week show a shift in its 50/200-day trend state from uptrend to mixed, suggesting the stock's near-term momentum has become less clearly directional. The stock's sector discount rank improved from #43 to #37 among Healthcare peers, indicating it has moved to a relatively more favorable valuation position within its sector. With a current valuation verdict of undervalued, INCY remains positioned as relatively inexpensive compared to comparable healthcare companies.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — INCY's 50/200-day trend state shifted from mixed to uptrend this week, according to TickrTrends' derived indicators. The Healthcare sector stock maintains an undervalued valuation verdict based on current analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is INCY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), INCY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is INCY's TickrTrends verdict?
INCY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does INCY compare to other Healthcare stocks?
INCY ranks #23 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is INCY overbought or oversold?
INCY's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does INCY report earnings next?
INCY's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does INCY usually beat earnings estimates?
Over its last 8 reported quarters INCY beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about INCY?
Of 28 analysts covering INCY, 12 rate it a buy, 15 a hold and 1 a sell - hold-leaning, with a consensus price target of $130 (+15.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
INCY vs ABT · INCY vs AMPH · INCY vs CI · INCY vs DCTH · INCY vs GEHC